Transparency information: Devgen nv
(Thomson Reuters ONE) -
Regulated information
Zwijnaarde - 8 April 2011 - In accordance with Article 15 §1 first paragraph of
the Act of May 2, 2007 on the disclosure of major shareholdings in listed
companies, Devgen nv hereby announces two consecutive capital increases for a
total of 4,586,794 new shares:
* on 4 April 2011, 4,584,549 new shares have been issued as the result of a
private placement,
* on 8 April 2011, 2.245 new shares have been issued as the result of the
exercise of warrants by employees of the company.
Information as of 8 April 2011:
Basic data
+----------------------------------------------------------------+----------+
|Total share capital (EUR) |1,819,755 |
+----------------------------------------------------------------+----------+
|Total number of securities conferring voting rights |24,263,436|
+----------------------------------------------------------------+----------+
|Total number of voting rights (the denominator): |24,263,436|
+----------------------------------------------------------------+----------+
|Total number of securities conferring voting rights by category:| N/A |
+----------------------------------------------------------------+----------+
|Total number of voting rights by category | N/A |
+----------------------------------------------------------------+----------+
Additional facts
+--------------------------------------------------------------------+---------+
|Total number of convertible bonds conferring voting rights | none |
+--------------------------------------------------------------------+---------+
|Total number of rights, materialized by certificates or not, to |1,526,704|
|subscribe to not yet issued securities which confer voting rights | |
+--------------------------------------------------------------------+---------+
|Total number of voting rights which result from the exercise of |1,526,704|
|these conversion or subscription rights | |
+--------------------------------------------------------------------+---------+
|Total number of shares without voting rights | none |
+--------------------------------------------------------------------+---------+
According to Article 14 of the Act of May 2, 2007 on the disclosure of major
shareholdings in listed companies, Devgen nv hereby makes public that it
received the following notification of shareholding:
Gimv NV and its daughter company Adviesbeheer Gimv Venture Capital 2010 NV have,
in concert with Biotech Fonds Vlaanderen (with as the ultimate shareholder The
Flemish Region) passed the threshold of 5% on April 4, 2011.
+------------------+-----------+-----------------+-----------------+-----------+
| |Denominator|Number of voting |Number of voting | % voting |
| | |rights before the|rights after the | rights |
| | | transaction | transaction | |
+------------------+-----------+-----------------+-----------------+-----------+
|Gimv NV |24,263,436 | 0 | 448,718 | 1.85 |
+------------------+ | +-----------------+-----------+
|Adviesbeheer Gimv | | | 64,103 | 0.26 |
|Venture Capital | | | | |
|2010 NV | | | | |
+------------------+ | +-----------------+-----------+
|Biotech Fonds | | | 1,025,641 | 4.23 |
|Vlaanderen NV | | | | |
+------------------+ | +-----------------+-----------+
|Total of in | | | 1,538,462 | 6.34 |
|concert acting | | | | |
|parties | | | | |
+------------------+-----------+-----------------+-----------------+-----------+
About Devgen nv
Devgen's mission is to deliver the next green revolution in rice to growers that
cultivate 60m ha rice in India and S.E. Asia.
Devgen uses advanced biotechnology and molecular breeding technology to develop
the Next Generation Hybrid Rice (NGHR) and crop protection solutions with a
superior environmental profile:
§ Devgen developed the next generation of hybrid rice, improving yield, seed
productivity, grain quality, and tolerance to biotic and abiotic stress factors.
Devgen strongly believes that this hybrid rice technology has the potential to
drive the accelerated conversion of varietal rice to hybrid rice.
§ Anticipating the need to increase insect resistance and drought/heat
tolerance in rice to a level that is beyond what can be achieved with classical
breeding, Devgen created a portfolio of biotech traits using own technology as
well as in-licensed technologies.
§ Devgen established an integrated seed business in India and Southeast Asia
through which its rice crops and technologies reach the market.
§ In India, Devgen complemented its hybrid rice business with geographically
and seasonally complementary crops: hybrid sorghum, pearl millet and sunflower.
§ In its Crop Protection unit, Devgen develops a novel nematicide, an agro-
chemical product that protects crops from damage by parasitic nematodes. This
product is sold in Turkey and in the US.
§ Devgen innovates in crop protection research and environment induced stress
tolerance for its own crops and providing technology to corporate partners.
Incorporated in 1997, Devgen has offices in Ghent (Belgium), and has
subsidiaries in Singapore, Hyderabad (India), Yogyakarta (Indonesia), General
Santos (Philippines) and Delaware (US), totaling about 280 employees.
For more information please contact:
Thierry Bogaert, CEO Wim Goemaere, CFO
Tel. +32 9 324 24 24 Tel. +32 9 324 24 24
Thierry.Bogaert(at)devgen.com Wim.Goemaere(at)devgen.com
Or visit: www.devgen.com
This press release may contain forward-looking statements containing the words
"anticipates", "expects" , "intends", "plans", "estimates", "may" and
"continues" as well as similar expressions. Such forward looking statements may
involve known and unknown risks, uncertainties and other factors which might
cause the actual results, performance or achievements of Devgen to be materially
different from any future results or achievements expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, among others: agricultural risks and difficulties,
including weather factors, diseases and pests, the costs and requirements of
regulatory compliance and the speed with which approvals are received; public
acceptance of biotechnology products; political, economic and social
developments in countries where Devgen operates and other risks and factors
detailed in the company's most recent annual report.
These forward looking statements speak only as of the date of publication of
this document. Devgen disclaims any obligation to update such forward looking
statements in this document to reflect any change in its expectations,
conditions or circumstances on which such statement is based, unless required by
law or regulation. This document does not constitute, or form part of, any offer
or invitation to sell or issue, or any solicitation of any offer, to purchase or
subscribe for any securities issued by Devgen NV.
PR ENG 8 April 2011:
http://hugin.info/135721/R/1504902/439841.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Devgen via Thomson Reuters ONE
[HUG#1504902]
Unternehmensinformation / Kurzprofil:
Datum: 08.04.2011 - 18:01 Uhr
Sprache: Deutsch
News-ID 53340
Anzahl Zeichen: 9447
contact information:
Town:
Gent-Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Transparency information: Devgen nv"
steht unter der journalistisch-redaktionellen Verantwortung von
Devgen (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
